Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109527 | 0.76 | TSHR (0.40) | CA12CA14TSHR | |
| SCHEMBL19636725 | 0.76 | SLC22A6 (0.39) | — | |
| SCHEMBL20593368 | 0.75 | TSHR (0.45) | CA12CA7CA9CA14TSHR | |
| SCHEMBL20593365 | 0.75 | TSHR (0.45) | CA12CA7CA9CA14TSHR | |
| SCHEMBL28902220 | 0.73 | TSHR (0.40) | TSHR | |
| SCHEMBL17495621 | 0.72 | MEN1 (0.51) | CA12CA7CA9 | |
| SCHEMBL15621164 | 0.70 | TET2 (0.45) | CA12CA14TSHR | |
| SCHEMBL6050259 | 0.69 | CYP2C19 (0.43) | TSHR | |
| SCHEMBL17495611 | 0.68 | MEN1 (0.46) | CA12CA7CA9CA14 | |
| SCHEMBL11136905 | 0.67 | SIGMAR1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434200-B2 | Compositions and associated methods for radioisotope-binding microparticles | BIOSPHERE MEDICAL, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20170333579-A1 | COMPOSITIONS AND ASSOCIATED METHODS FOR RADIOISOTOPE-BINDING MICROPARTICLES | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333579-A1 | COMPOSITIONS AND ASSOCIATED METHODS FOR RADIOISOTOPE-BINDING MICROPARTICLES | CD47, CD68, MPI | CA12 704/4885CA7 1706/4885CA9 731/4885 |
| US-10434200-B2 | Compositions and associated methods for radioisotope-binding microparticles | CD47, CD68, MPI | CA12 704/4885CA7 1706/4885CA9 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.